| This week's sponsor is McKesson Life Sciences. | | | |
Today's Rundown Neurocrine pays Voyager $165M for neurological gene therapies Celgene inks $1B deal for a preclinical epigenetic blood cancer drug from Canada Pfizer/Lilly NGF pain drug wins again, but safety concern won’t go away Aldeyra boosts eye disease pipeline with $10M Helio Vision buy Langer’s Lyndra Therapeutics bags $55M to advance ‘ultralong-acting’ pill Takeda-backed Maverick promotes R&D staff for T-cell push Takeda’s dengue shot, rival to Sanofi's Dengvaxia, hits the mark in massive phase 3 study Novartis: Alternative payments will ‘reset the paradigm’ for covering gene, cell therapies Featured Story | | | Tuesday, January 29, 2019 Neurocrine Biosciences is set to pay Voyager Therapeutics $165 million upfront for the rights to a clutch of gene therapies. The deal sees Neurocrine commit to $1.7 billion in milestones in return for Parkinson’s disease program VY-AADC and other assets. |
|
|
Top Stories Tuesday, January 29, 2019 Celgene has signed on to a deal worth about $1 billion for a Canadian preclinical asset: a first-in-class small molecule that targets protein-protein interactions and epigenetic regulation in leukemia and lymphoma. Tuesday, January 29, 2019 Pfizer and Lilly now have two pivotal trials showing NGF blocker tanezumab reduces pain in arthritis, but cases of rapid joint damage are still seen, this time including osteonecrosis. Tuesday, January 29, 2019 Aldeyra Therapeutics is acquiring Helio Vision for $10 million upfront, adding a retinal disease drug to its pipeline. The candidate, developed for the treatment of proliferative vitreoretinopathy, should head into the clinic this year, with data to come in 2020. Tuesday, January 29, 2019 Lyndra Therapeutics has raised a $55 million series B round to expand its early-stage pipeline of “ultralong-acting” medicines, boost manufacturing and carry out a phase 2 trial of a long-acting pill for the treatment of schizophrenia. Tuesday, January 29, 2019 T-cell startup Maverick Therapeutics has promoted Robert DuBridge and Chad May. The executives, who have been at Maverick since its inception, are stepping into new roles in the biotech’s R&D team. Tuesday, January 29, 2019 It’s no secret Sanofi has had trouble with its world-first dengue vaccine, Dengvaxia, but that hasn't dissuaded Takeda. Its own dengue shot met its goal in a pivotal phase 3 study that covered eight countries and more than 20,000 participants. Tuesday, January 29, 2019 Novartis is pleased that drug-cost watchdog ICER called its spinal muscular atrophy gene therapy cost-effective even if priced at $2 million, an executive said during a FierceBiotech discussion this week. But as costly gene and cell therapies proliferate, biopharma will have to work with insurers on alternative payment models, the panelists agreed. | This week's sponsor is ExL Events. | | | |
Enrollment Showcase | | | Sponsored by: Drexel University Online Drexel University’s online graduate programs in biomedicine, clinical research, drug discovery, and molecular medicine were developed with working professionals in mind, providing you with the education, practical skills, and competitive edge you need to be successful in your career. Learn more. |
|
|
Resources Sponsored by: Veradigm Clinical trials take too long and cost too much—here's what needs to change. Sponsored by: AlphaSense It’s never been more challenging to stay on top of competitive factors impacting your industry. Discover how AI can help competitive teams achieve more proactive market intelligence. Sponsored by: Reprints Desk, Inc. Go from Search to Full-Text Scientific Papers in a Single Click! Sponsored by: Blue Latitude Health This white paper consists of original data and expert interviews. Download it today for exclusive tools, tips and analysis on achieving launch excellence in challenging pharma markets. Sponsored by: Outer Edge Technology With FDA approval imminent, start-up Life Sciences company partners with an industry focused MSP to design and manage its regulated cloud-based infrastructure to speed time to market. Sponsored by: DeciBio Consulting With the liquid biopsy market maturing and >80 companies still competing with liquid biopsy offerings, it is crucial for investors to be able to cut through the noise and identify the winners. Presented by: Veeva Share your thoughts on the life sciences industry's progress in improving study execution. Presented by: Aprecia Get ahead of looming challenges in the market that include both generic products and new branded drugs. Sponsored by: Oracle Health Sciences New infographic shows trends in clinical development and the impact on randomization and trial supply management technology (RTSM). Sponsored by: Veeva Reduce the effort to create submissions and track registrations with a move to unified RIM. Watch the on-demand webinar. Sponsored by: Biotech Primer The Biopharma industry is moving at lightning speed and it can be a challenge to keep pace. Here at Biotech Primer we spend hours each week researching, writing, and editing original content for the Biotech Primer WEEKLY with one goal in mind: to help everyone better understand the latest science and technology driving today’s healthcare industry. BIO CEO & Investor Conference February 11-12, 2019 | New York Marriott Marquis Asia-Pacific Compliance Training for Life Sciences Professionals March 4-7, 2019 | Singapore 2019 Bridging Clinical Research & Clinical Health Care Collaborative March 4–5, 2019 | National Academy of Sciences | Washington, D.C. BIO Asia International Conference March 5-6, 2019 | Grand Hyatt Tokyo | Tokyo, Japan Drug Development Boot Camp® 2019 November 20-21, 2019 | Boston, MA | Register and start preparing Today! | 